Tirzepatide
ContestedGLP-1
Our read of public sources: some pharmacies compound it under a legal theory — a differentiated-formulation argument, or in anticipation of a pending committee recommendation — that no court ruling or final FDA rule has settled either way. We're flagging this as actively debated, not as a green or red light. This is not a legal determination; verify independently before relying on it.
Not legal advice. Every status on this page is our own reading of public FDA guidance, shortage listings, and committee materials — it has not been reviewed by an attorney and is not a legal determination. "Contested" means pharmacies and regulators publicly disagree, not that we're resolving the disagreement. Verify independently, and check with counsel, before relying on any entry here.
Current status
Shortage-based compounding exception ended Feb 18, 2025. Some 503A pharmacies (e.g. Red Rock Pharmacy) continue compounding by adding an ingredient such as glycine, arguing the resulting product is not 'essentially a copy' of the approved drug. This legal theory is unsettled — a May 2025 court ruling upheld the shortage-list removal, and FDA has proposed permanently excluding tirzepatide from the 503B bulk substances list.
Shortage-list history: Removed from FDA shortage list December 2024.
Last changed: 2026-08-14
Enforcement history
- 2026-08-24
FDA warning letters to five online vendors (Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, TXP Innovations) for unapproved-drug sales; FDA applied a 'net impression' standard rejecting RUO labels as a shield.
Source